Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro M Machado

Showing results (81-90 of 227) with videos related to

Pageof 23
Sort By:
Annals of the Rheumatic Diseases|June 25, 2026
Comparison of the established ASAS definition and preliminary proposed data-driven cut-offs for inflammatory and structural MRI lesions in the sacroiliac joints for eligibility of patients with nonradiographic axial spondyloarthritis in clinical trialsXenofon Baraliakos, Victoria Navarro-Compán, Sofia Ramiro, et al.
The Lancet. Neurology|November 10, 2015
MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort studyJasper M Morrow, Christopher D J Sinclair, Arne Fischmann, et al.
BMJ Open|May 3, 2024
Factors influencing the outcomes of non-pharmacological interventions for managing fatigue across the lifespan of people living with musculoskeletal (MSK) conditions: a scoping review protocolKatie Fishpool, George Young, Coziana Ciurtin, et al.
RMD Open|August 6, 2016
Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatologyChristian Beyer, Sofia Ramiro, Francisca Sivera, et al.
Annals of the Rheumatic Diseases|November 7, 2020
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countriesChristian Dejaco, Alessia Alunno, Johannes Wj Bijlsma, et al.
Annals of the Rheumatic Diseases|February 18, 2022
Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment'Ricardo J O Ferreira, Paco M J Welsing, Johannes Wg Jacobs, et al.
Arthritis Care & Research|September 22, 2025
Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims DataH Berk Degirmenci, Christine E Peloquin, Maggie Westerland, et al.
Rheumatology and Therapy|December 22, 2020
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 StudiesXenofon Baraliakos, Filip Van den Bosch, Pedro M Machado, et al.
Arthritis Care & Research|March 18, 2025
Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical TrialsRaisa Lomanto Silva, Manuel Carpio Tumba, Sneha Gupta, et al.
RMD Open|August 30, 2017
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritisJürgen Braun, Xenofon Baraliakos, Kay-Geert Hermann, et al.
Pageof 23

Showing results (81-90 of 227) with videos related to

Sort By:
Pageof 23
Annals of the Rheumatic Diseases|June 25, 2026
Comparison of the established ASAS definition and preliminary proposed data-driven cut-offs for inflammatory and structural MRI lesions in the sacroiliac joints for eligibility of patients with nonradiographic axial spondyloarthritis in clinical trialsXenofon Baraliakos, Victoria Navarro-Compán, Sofia Ramiro, et al.
The Lancet. Neurology|November 10, 2015
MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort studyJasper M Morrow, Christopher D J Sinclair, Arne Fischmann, et al.
BMJ Open|May 3, 2024
Factors influencing the outcomes of non-pharmacological interventions for managing fatigue across the lifespan of people living with musculoskeletal (MSK) conditions: a scoping review protocolKatie Fishpool, George Young, Coziana Ciurtin, et al.
RMD Open|August 6, 2016
Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatologyChristian Beyer, Sofia Ramiro, Francisca Sivera, et al.
Annals of the Rheumatic Diseases|November 7, 2020
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countriesChristian Dejaco, Alessia Alunno, Johannes Wj Bijlsma, et al.
Annals of the Rheumatic Diseases|February 18, 2022
Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment'Ricardo J O Ferreira, Paco M J Welsing, Johannes Wg Jacobs, et al.
Arthritis Care & Research|September 22, 2025
Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims DataH Berk Degirmenci, Christine E Peloquin, Maggie Westerland, et al.
Rheumatology and Therapy|December 22, 2020
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 StudiesXenofon Baraliakos, Filip Van den Bosch, Pedro M Machado, et al.
Arthritis Care & Research|March 18, 2025
Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical TrialsRaisa Lomanto Silva, Manuel Carpio Tumba, Sneha Gupta, et al.
RMD Open|August 30, 2017
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritisJürgen Braun, Xenofon Baraliakos, Kay-Geert Hermann, et al.
Pageof 23